Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 "Ask CAS" for self-help around the clock
NEWS
NEWS
         SEP 09
                 CA/CAplus records now contain indexing from 1907 to the
                 present
NEWS
         AUG 05
                New pricing for EUROPATFULL and PCTFULL effective
                 August 1, 2003
NEWS
     5
         AUG 13
                 Field Availability (/FA) field enhanced in BEILSTEIN
                Data available for download as a PDF in RDISCLOSURE
NEWS
         AUG 18
     6
NEWS
     7
         AUG 18
                 Simultaneous left and right truncation added to PASCAL
                FROSTI and KOSMET enhanced with Simultaneous Left and Righ
NEWS
         AUG 18
                 Truncation
NEWS 9
        AUG 18
                Simultaneous left and right truncation added to ANABSTR
NEWS 10
        SEP 22
                DIPPR file reloaded
NEWS 11 DEC 08
                INPADOC: Legal Status data reloaded
NEWS 12
        SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded
NEWS 17 DEC 08 CABA reloaded with left truncation
NEWS 18 DEC 08
                IMS file names changed
NEWS 19 DEC 09
                Experimental property data collected by CAS now available
                 in REGISTRY
NEWS 20
        DEC 09
                 STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 21
        DEC 17
                DGENE: Two new display fields added
NEWS 22
        DEC 18
                BIOTECHNO no longer updated
NEWS EXPRESS
             NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
             MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:07:49 ON 18 DEC 2003

=> file medline, dgene, wpids, uspatful, biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY 0.21

SESSION 0.21

FILE 'MEDLINE' ENTERED AT 15:08:02 ON 18 DEC 2003

FILE 'DGENE' ENTERED AT 15:08:02 ON 18 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 15:08:02 ON 18 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 15:08:02 ON 18 DEC 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:08:02 ON 18 DEC 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

=> s testicular cancer and treatment

8223 TESTICULAR CANCER AND TREATMENT

=> s polpeptide and l1

4 POLPEPTIDE AND L1

=> d l2 ti abs ibib tot

ANSWER 1 OF 4 USPATFULL on STN

ΤI Human tumor necrosis factor receptor TR9

AB The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:300816 USPATFULL

TITLE: INVENTOR(S): Human tumor necrosis factor receptor TR9 Ni, Jian, Germantown, MD, UNITED STATES Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Fan, Ping, Potomac, MD, UNITED STATES

Gentz, Reiner L., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S):

Human Genome Sciences, Inc., Rockville, MD, UNITED

STATES, 20850 (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: APPLICATION INFO.:

US 2002168359 20021114 A1

RELATED APPLN. INFO.:

A1 20020110 (10) US 2002-41574

Division of Ser. No. US 2000-527236, filed on 16 Mar 2000, PATENTED Continuation-in-part of Ser. No. US

1998-95094, filed on 10 Jun 1998, PENDING

NUMBER	DATE

PRIORITY INFORMATION:

US 1999-134220P 19990514 (60)

US 1999-126019P 19990324 (60) US 1997-52991P 19970611 (60)

DOCUMENT TYPE:

Utility ' APPLICATION

FILE SEGMENT: LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 9755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 2 OF 4 USPATFULL on STN L2

Novel inhibitor of hepatocyte growth factor activator for use in TΤ

modulation of angiogenesis and cardiovascularization

Compositions and methods are disclosed for stimulating or inhibiting AB angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy.

In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:227938 USPATFULL

TITLE: Novel inhibitor of hepatocyte growth factor activator

for use in modulation of angiogenesis and

cardiovascularization

Gurney, Austin L., Belmont, CA, UNITED STATES INVENTOR(S):

Kirchhofer, Daniel K., Los Altos, CA, UNITED STATES

Wood, William I., Hillsborough, CA, UNITED STATES

PATENT ASSIGNEE(S): GENERITECH, INC. (U.S. corporation)

KIND NUMBER DATE -----PATENT INFORMATION: US 2002123091 A1 20020905 APPLICATION INFO.: US 2000-742201 A1 20001219 (9)

NUMBER DATE -----WO 2000-US3565 20000211 WO 2000-US6884 20000315 PRIORITY INFORMATION:

US 2000-253665P 20001128 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA,

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 6377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2ANSWER 3 OF 4 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AΒ The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use of such respiratory system antiqens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated

respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:165192 USPATFULL

TITLE:

Nucleic acids, proteins, and antibodies

INVENTOR(S):

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMB	ER KIND	DATE	
		<b></b>		
PATENT INFORMATION:	US 200208	6821 A1	20020704	
	US 200312	5246 A9	20030703	
APPLICATION INFO.:	US 2001-7	64881 A1	20010117	(9)

NUMBER DATE

PRIORITY INFORMATION:

US 2000-179065P 20000131 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

LINE COUNT: 27531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 4 USPATFULL on STN

TI Antibodies to human tumor necrosis factor receptor TR9

AB The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:57390 USPATFULL

TITLE:

Antibodies to human tumor necrosis factor receptor TR9

INVENTOR(S):

Ni, Jian, Rockville, MD, United States Yu, Guo-Liang, Berkeley, CA, United States Fan, Ping, Gaithersburg, MD, United States Gentz, Reiner L., Rockville, MD, United States

PATENT ASSIGNEE(S):

Human Genome Sciences, Inc., Rockville, MD, United

States (U.S. corporation)

Continuation-in-part of Ser. No. US 1998-95094, filed RELATED APPLN. INFO.:

on 10 Jun 1998

NUMBER DATE -----US 1997-52991P 19970611 (60) US 1999-126019P 19990324 (60) PRIORITY INFORMATION:

US 1999-134220P 19990514 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

Spector, Lorraine PRIMARY EXAMINER: ASSISTANT EXAMINER: O'Hara, Eileen B.

Human Genome Sciences, Inc. LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS: 10

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 11 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 8936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s secreted proteins

L3 252071 SECRETED PROTEINS

=> s 13 and 11

382 L3 AND L1

=> s 14 and 12

4 L4 AND L2

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 4 USPATFULL on STN

ΤI Human tumor necrosis factor receptor TR9

AB The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:

2002:300816 USPATFULL

TITLE: INVENTOR (S):

PATENT ASSIGNEE(S):

Human tumor necrosis factor receptor TR9 Ni, Jian, Germantown, MD, UNITED STATES Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Fan, Ping, Potomac, MD, UNITED STATES

Gentz, Reiner L., Rockville, MD, UNITED STATES Human Genome Sciences, Inc., Rockville, MD, UNITED

STATES, 20850 (U.S. corporation)

NUMBER KIND -----US 2002168359 A1 20021114 US 2002-41574 A1 20020110 (10) PATENT INFORMATION: APPLICATION INFO.:

Division of Ser. No. US 2000-527236, filed on 16 Mar RELATED APPLN. INFO.: 2000, PATENTED Continuation-in-part of Ser. No. US

1998-95094, filed on 10 Jun 1998, PENDING

NUMBER DATE -----US 1999-134220P 19990514 (60) US 1999-126019P 19990324 (60) PRIORITY INFORMATION: US 1997-52991P 19970611 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24 EXEMPLARY CLAIM: 1

hypertrophy.

NUMBER OF DRAWINGS: 11 Drawing Page(s)

LINE COUNT: 9755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 4 USPATFULL on STN

TI Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization

AB Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac

In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:227938 USPATFULL

TITLE: Novel inhibitor of hepatocyte growth factor activator

for use in modulation of angiogenesis and

cardiovascularization

INVENTOR(S): Gurney, Austin L., Belmont, CA, UNITED STATES

Kirchhofer, Daniel K., Los Altos, CA, UNITED STATES Wood, William I., Hillsborough, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA,

94080

NUMBER OF CLAIMS: 54 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 6377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "respiratory system antigens," and the use

of such respiratory system antigens for detecting disorders of the respiratory system, particularly the presence of cancer of respiratory system tissues and cancer metastases. More specifically, isolated respiratory system associated nucleic acid molecules are provided encoding novel respiratory system associated polypeptides. Novel respiratory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human respiratory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the respiratory system, including cancer of respiratory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:165192 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

		NUMBER	KIND	DATE	
PATENT INFORMATION:		2002086821	A1	20020704	
	US	2003125246	A9	20030703	
APPLICATION INFO.:	US	2001-764881	A1	20010117	(9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-179065P 20000131 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 4 USPATFULL on STN

TI Antibodies to human tumor necrosis factor receptor TR9

The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are antibodies vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57390 USPATFULL

TITLE: Antibodies to human tumor necrosis factor receptor TR9

INVENTOR(S): Ni, Jian, Rockville, MD, United States
Yu, Guo-Liang, Berkeley, CA, United States

Fan, Ping, Gaithersburg, MD, United States Gentz, Reiner L., Rockville, MD, United States

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United

States (U.S. corporation)

NUMBER KIND DATE

\_\_\_\_\_\_ US 6358508 B1 20020319 US 2000-527236 20000316 (9) PATENT INFORMATION:

APPLICATION INFO.:

Continuation-in-part of Ser. No. US 1998-95094, filed RELATED APPLN. INFO.:

on 10 Jun 1998

NUMBER DATE -----

US 1997-52991P 19970611 (60) US 1999-126019P 19990324 (60) PRIORITY INFORMATION:

US 1999-134220P 19990514 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

Spector, Lorraine PRIMARY EXAMINER: O'Hara, Eileen B. ASSISTANT EXAMINER:

LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.

NUMBER OF CLAIMS: 10 EXEMPLARY CLAIM: 1

11 Drawing Figure(s); 11 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 8936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e ruben,	s/au	
E1	1	RUBEN ZANCHETTA JOSE/AU
E2	2	RUBEN ZORRO/AU
E3	0>	RUBEN, S/AU
E4	8	RUBENACH B/AU
E5	8	RUBENACH BERNHARD/AU
E6	1	RUBENACH GERZ K/AU
E7	1	RUBENACH I/AU
E8	1	RUBENACH J/AU
E9	6	RUBENACH S/AU
E10	4	RUBENACH SALLY/AU
E11	1	RUBENACH SALLY E/AU
E12	1	RUBENACK R D/AU
=> e rosen,c	:/au	
=> e rosen,c	:/au 2	ROSEN ZVI MICHAL/AU
•	•	ROSEN ZVI MICHAL/AU ROSEN ZWEIG JAMES/AU
E1	2 1	
E1 E2	2 1 0>	ROSEN ZWEIG JAMES/AU
E1 E2 E3	2 1	ROSEN ZWEIG JAMES/AU ROSEN,C/AU
E1 E2 E3 E4	2 1 0>	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU
E1 E2 E3 E4 E5	2 1 0> 1 1	ROSEN ZWEIG JAMES/AU ROSEN,C/AU ROSENA BRUCE R/AU ROSENABUM S/AU ROSENACKER A F/AU
E1 E2 E3 E4 E5 E6	2 1 0> 1 1	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU ROSENABUM S/AU
E1 E2 E3 E4 E5 E6 E7	2 1 0> 1 1 1	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU ROSENABUM S/AU ROSENACKER A F/AU ROSENACKER ARTHUR F/AU
E1 E2 E3 E4 E5 E6 E7 E8	2 1 0> 1 1 1 1	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU ROSENABUM S/AU ROSENACKER A F/AU ROSENACKER ARTHUR F/AU ROSENADA CEPERO R/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9	2 1 0> 1 1 1 1 4 1	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU ROSENABUM S/AU ROSENACKER A F/AU ROSENACKER ARTHUR F/AU ROSENADA CEPERO R/AU ROSENAGER L/AU
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10	2 1 0> 1 1 1 1 4 1	ROSEN ZWEIG JAMES/AU ROSEN, C/AU ROSENA BRUCE R/AU ROSENABUM S/AU ROSENACKER A F/AU ROSENACKER ARTHUR F/AU ROSENADA CEPERO R/AU ROSENAGER L/AU ROSENAK B/AU